Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

Clinical trial NCT07389629 · RECRUITING

Trial details

NCT number: NCT07389629
Sponsor: Sun Yat-sen University
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Iparomlimab and Tuvonralimab Clear Cell Renal Cell Carcinoma Neoadjuvant Therapy

Start date: 2025-11-21
Primary completion: 2027-12-31
Enrollment: 25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.